Analysts Offer Insights on Healthcare Companies: Rein Therapeutics (RNTX), Zimmer Biomet Holdings (ZBH) and Theravance Biopharma (TBPH)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rein Therapeutics (RNTX – Research Report), Zimmer Biomet Holdings (ZBH – Research Report) and Theravance Biopharma (TBPH – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rein Therapeutics (RNTX)
H.C. Wainwright analyst Brandon Folkes maintained a Buy rating on Rein Therapeutics yesterday and set a price target of $10.00. The company’s shares closed last Wednesday at $1.21.
According to TipRanks.com, Folkes is a 3-star analyst with an average return of
Currently, the analyst consensus on Rein Therapeutics is a Moderate Buy with an average price target of $10.00.
See today’s best-performing stocks on TipRanks >>
Zimmer Biomet Holdings (ZBH)
In a report issued on January 20, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Zimmer Biomet Holdings, with a price target of $101.00. The company’s shares closed last Wednesday at $86.55.
According to TipRanks.com, Chadha is a 3-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Zimmer Biomet Holdings with a $100.47 average price target, which is a 15.4% upside from current levels. In a report issued on January 5, Evercore ISI also upgraded the stock to Buy with a $120.00 price target.
Theravance Biopharma (TBPH)
In a report released yesterday, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Theravance Biopharma, with a price target of $20.00. The company’s shares closed last Wednesday at $20.37.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Theravance Biopharma with a $28.40 average price target, which is a 39.2% upside from current levels. In a report issued on January 12, TipRanks – Google also reiterated a Buy rating on the stock with a $22.00 price target.
